Who Qualifies for Direct Meds GLP-1 Treatment BMI and Clinical Eligibility Criteria To qualify for GLP-1 treatment through Direct Meds, patients generally need to meet one of the following BMI-based criteria: A BMI of 30 or above the standard clinical classification for obesity without any additional qualifying condition requirement
The FDA has a drug shortage list, and injectable semaglutide was in low supply for three years, from early 2022 to February 2025
Unlike standard pharmacogenomic tests, this assessment maps your FTO rs9939609 variant (appetite and fat storage), MC4R rs17782313 status (central appetite control), and GIPR rs1800437 profile (glucose-dependent insulinotropic peptide sensitivity)all critical for predicting semaglutide response
This was a 7.56 percent increase from 767 million ($907 million USD) in 2021
It is recommended that you start with the lowest concentration and then increase the amount gradually
Some insurance doesnt cover it